Related references
Note: Only part of the references are listed.Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study
Suresh K. Agarwal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum
Haidar Akl et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199
Edna F. Choo et al.
DRUG METABOLISM AND DISPOSITION (2014)
Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update
Natalie L. Trevaskis et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine
SM Khoo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2001)